Capricorn Fund Managers Dumps $18.4 Million Worth of Waystar Stock in Q1

Capricorn Fund Managers cut its Waystar stake by 692,554 shares in Q1 2026, an estimated $18.38 million sale that reduced the position’s quarter-end value by $23.08 million. After the filing, Capricorn still held 45,709 shares worth $1.10 million, equal to 0.17% of AUM and outside its top five holdings. The move is notable for positioning, but it is likely more of a fund-specific portfolio adjustment than a fundamental catalyst for Waystar.

Analysis

Capricorn’s exit is more informative about portfolio construction than about a wholesale indictment of the business: when a sub-2% position is cut to near-irrelevance, it usually signals either a better risk-adjusted opportunity set elsewhere or a loss of conviction in near-term multiple expansion. The important second-order read-through is that new-issue SaaS names without strong post-IPO sponsorship can become flow-driven trading vehicles; once a prominent holder reduces, the stock loses an incremental bid and can drift lower even without a fundamentals break.

The market is likely underpricing how sensitive Waystar’s tape is to sentiment around healthcare software and “AI-enabled SaaS” multiples. If investors keep treating it like a generic software compounder, upside is capped by valuation compression; if they re-rate it as a cash-generative vertical workflow platform with sticky customer economics, the stock can recover materially from depressed levels. The key battleground is not revenue growth alone, but whether free cash flow conversion stays high enough to justify a premium multiple in a slower-rerating environment.

The contrarian setup is that this may already be a de-risked name: a roughly one-third drawdown over the past year and a valuation near mid-teens free cash flow can attract bottom-fishing once selling pressure from transient holders is exhausted. The risk is that any near-term guidance miss or evidence of slower customer expansion triggers another leg down because there is no deep institutional “must-own” base yet. In that scenario, the stock can remain range-bound for months even if fundamentals stay intact.

The fastest catalyst to reverse the trend is a clean quarter showing durable bookings and no AI capex drag on margins; absent that, the name remains hostage to factor flows into/out of healthcare tech and lower-duration growth. Watch for secondary effects on adjacent healthcare payments and revenue-cycle peers: a stabilization in Waystar could lift the whole group, while continued weakness would reinforce skepticism toward post-IPO software stories.

Key Decisions for Investors

• Avoid catching the falling knife in WAY for now; wait for either a post-earnings stabilization or a technical reclaim of prior support before initiating a long, since flow-driven downdrafts can persist 4-8 weeks after a major holder exit.
• If looking for a speculative long, buy WAY only as a defined-risk call spread into the next earnings cycle; upside is from multiple re-rating, while the downside is another 15-20% de-rating on any guidance softness.
• Pair trade idea: long high-quality healthcare workflow software with stronger sponsorship, short WAY as the weaker post-IPO beta name; the goal is to isolate factor/flow risk rather than sector exposure.
• For event-driven traders, set a trigger to add WAY only if quarterly free cash flow margin and customer growth both accelerate; that would confirm the market is wrong and could produce a 20-30% rerating over 2-3 months.
• If WAY loses recent lows on above-average volume, consider a tactical short or put spread for a 1-2 month horizon, as low-ownership names often overshoot once a visible seller is absorbed.